These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 32697352)

  • 1. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
    Durm GA; Jabbour SK; Althouse SK; Liu Z; Sadiq AA; Zon RT; Jalal SI; Kloecker GH; Williamson MJ; Reckamp KL; Langdon RM; Kio EA; Gentzler RD; Adesunloye BA; Harb WA; Walling RV; Titzer ML; Hanna NH
    Cancer; 2020 Oct; 126(19):4353-4361. PubMed ID: 32697352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
    Anouti B; Althouse S; Durm G; Hanna N
    Clin Lung Cancer; 2020 May; 21(3):288-293. PubMed ID: 32143966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
    Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
    Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
    Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
    Ross HJ; Kozono D; Wang XF; Urbanic JJ; Williams TM; Nelson GD; Carbone DP; Chung D; Robb R; Byun WY; Talabere T; DuFrane C; Bara I; Schulze K; Brockman M; Gao J; Vokes EE; Stinchcombe TE
    JAMA Oncol; 2024 Sep; 10(9):1212-1219. PubMed ID: 39052256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
    Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
    Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
    Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
    JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
    Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
    Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
    Chang AEB; Piper-Vallillo AJ; Mak RH; Lanuti M; Muzikansky A; Rotow J; Jänne PA; Mino-Kenudson M; Swanson S; Wright CD; Kozono D; Marcoux P; Piotrowska Z; Sequist LV; Willers H
    Oncologist; 2024 Jul; 29(7):609-618. PubMed ID: 38761385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Senan S; Brade A; Wang LH; Vansteenkiste J; Dakhil S; Biesma B; Martinez Aguillo M; Aerts J; Govindan R; Rubio-Viqueira B; Lewanski C; Gandara D; Choy H; Mok T; Hossain A; Iscoe N; Treat J; Koustenis A; San Antonio B; Chouaki N; Vokes E
    J Clin Oncol; 2016 Mar; 34(9):953-62. PubMed ID: 26811519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
    Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
    Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
    Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
    Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
    Horinouchi H; Nogami N; Saka H; Nishio M; Tokito T; Takahashi T; Kasahara K; Hattori Y; Ichihara E; Adachi N; Noguchi K; Souza F; Kurata T
    Cancer Sci; 2021 Aug; 112(8):3255-3265. PubMed ID: 34036692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
    Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
    Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.